Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 3Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1HER2-expressing Cancers 1Composite Lymphoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × ALX148 × Clear all
NCT05524545 2025-07-25

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

ALX Oncology Inc.

Phase 1 Completed
36 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡